Andrew Guggenhime, PRESIDENT AND CFO at Vaxcyte, Inc. (PCVX), sold 10,515 shares at $116.29 ($1.2M) on 2024-09-18, disclosed to the SEC on 2024-09-19.
Scheduled sale ($1.2M) by PRESIDENT AND CFO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $115.60 | 5,485 | $634K | 51.9% |
| 2 | $116.29 | 1,686 | $196K | 16.1% |
| 3 | $116.29 | 1,686 | $196K | 16.1% |
| 4 | $117.53 | 829 | $97K | 8.0% |
| 5 | $117.53 | 829 | $97K | 8.0% |
| Total | $116.13 avg | 10,515 |
| $1.2M |
| 100% |
| Filing → |
| PCVX | SELL | 2026-06-18 | $530K | — | Filing → |
| PCVX | SELL | 2025-02-19 | $1.3M | — | Filing → |
| PCVX | SELL | 2025-01-22 | $1.4M | — | Filing → |